TG Therapeutics (NASDAQ:TGTX) announces positive topline results from a Phase 3 clinical trial, UNITY-CLL,
comparing unbralisib plus ublituximab (U2) to obinutuzumab plus
chlorambucil in patients with previously untreated
relapsed/refractory chronic lymphocytic leukemia (CLL).
Based on a prespecified interim analysis by the
independent Data Safety Monitoring Board, treatment with U2 resulted in a
statistically significant improvement in progression-free survival
(PFS). As a result, the study will be stopped early.
Management will host a conference call this morning at 8:30 am ET to discuss the results.
https://seekingalpha.com/news/3569023-tg-therapeutics-up-34-premarket-on-positive-umbralisib-data
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.